Abstract
The pharmacotherapeutic management of neurological and psychiatric disorders relies primarily on the modulation of central nervous system (CNS) neurotransmission with drugs that intervene at chemical synapses. The receptors, transporters, and enzymes for the dopaminergic, serotonergic, and noradrenergic systems are the most common neuropsychiatric drug targets, because these neurotransmitter systems play a central role in the regulation of a range of cognitive and motor behaviors. The key to understanding or anticipating the clinical profile (dose-effect) of a particular drug is to have an appreciation for both its pharmacodynamic and pharmacokinetic properties.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Jones BJ, Blackburn TP. The medical benefit of 5-HT research. Pharmacol Biochem Behav. 2002;71:555–568.
Xu Y, Ito A, Arai R. Immunohistochemical localization of monoamine oxidase type B in the taste bud of the rat. Neurotoxicology. 2004;25:149–154.
Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999;51:593–628.
Hall DA, Strange PG. Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors. Br J Pharmacol. 1997;121:731–736.
Wilson J, Lin H, Fu D, Javitch JA, Strange PG. Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation. J Neurochem. 2001;77:493–504.
Weiner DM, Burstein ES, Nash N, et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 2001;299:268–276.
Schetz JA. Allosteric modulation of dopamine receptors. Mini-review. Med Chem. 2004; in press.
Limbird LL. Identification of receptors using direct radioligand binding techniques. In: Cell Surface Receptors: A short course on Theory and Methods. Martinus Nijhoff Publishing, 1986:51–96.
Cheng Y-C, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099–3108.
Ehlert FJ. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mole Pharmacol. 1988;33:187–194.
Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev. 2002; 54:323–374.
Ariens EJ. Affinity and intrinsic activity in the theory of competitive inhibition. Arch Int Pharmacodyn Ther. 1954;99:32–49.
Ritschel WA. Pharmacokinetics in the aged. In: Pagliaro LA and Pagliaro AM, eds. Pharmacologic aspects of aging. Mosby, 1983.
Ascher JA, Cole JO, Colin, J-N, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56:395–401
Bondarev ML, Bondareva TS, Young R, Glennon RA. Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol. 2003;474:85–93.
Tsao P, Cao T, von Zastrow M. Role of endocytosis in mediating downregulation of G-protein-coupled receptors. Trends Pharmacol Sci. 2001;22:91–96.
Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci. 2003;4:13–25.
Kumer SC, Vrana KE. Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 1996;67:443–462.
Hensler JG. Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci. 2003;72:1665–1682.
Blier P. Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry. 2001; 62Suppl 15:12–17.
Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci. 2002;22:6766–6772.
Tallman JF, Primus RJ, Brodbeck R, et al. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997;282:1011–1019.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Schetz, J.A. (2005). Pharmacotherapeutic Principles of Neurological and Psychiatric Disorders. In: Tarazi, F.I., Schetz, J.A. (eds) Neurological and Psychiatric Disorders. Current Clinical Neurology. Humana Press. https://doi.org/10.1385/1-59259-856-0:029
Download citation
DOI: https://doi.org/10.1385/1-59259-856-0:029
Publisher Name: Humana Press
Print ISBN: 978-1-58829-369-5
Online ISBN: 978-1-59259-856-4
eBook Packages: MedicineMedicine (R0)